Social Media Ideas for Aravax

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders

Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say t...

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera

AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.

<![CDATA[Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ]]>

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead mov...

Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences

Earlier this month Forte announced positive results for its lead candidate FB102, from a Phase Ib trial assessing the anti-CD122 monoclonal antibody in vitiligo. FB102 achieved a 2...

<![CDATA[Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D]]>

A single RSV shot emerges as a promising new shield for infants at risk of severe disease

Viral infections that attack the lungs are among the leading reasons infants are hospitalized. A new treatment may offer protection against these infections that is as effective an...

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medi...

Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmuneâ„¢Webinar to include an overv...